The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Despite there being a valid 'cspec' property in the messages there's a discrepancy in message contents and CSPEC data: * Message Gene: undefined CSPEC Genes: [] * Message MONDOs: MONDO:0044970 CSPEC MONDO: []
  • No CSPEC computed assertion could be determined for this classification!


Variant: NC_012920.1(MT-ND2):m.4681T>C

CA120644

9721 (ClinVar)

Gene: N/A
Condition: mitochondrial disease
Inheritance Mode: Mitochondrial inheritance
UUID: 92f2d6ba-328b-45c6-87db-439696ffdd80
Approved on: 2023-10-23
Published on: 2025-06-05

HGVS expressions

NC_012920.1:m.4681T>C
J01415.2:m.4681T>C
ENST00000361453.3:c.212T>C

Uncertain Significance

Met criteria codes 3
PM2_Supporting PP3 PS3_Supporting

Evidence Links 1

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Mitochondrial Disease Nuclear and Mitochondrial Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1_mtDNA

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Mitochondrial Diseases VCEP
The m.4681T>C (p.L71P) variant in MT-ND2 has been reported in one individual with primary mitochondrial disease to date, in a boy with Leigh syndrome and generalized muscle atrophy (PMIDs: 16996290, 16738010). He had elevated blood and cerebrospinal fluid lactate. Complex I deficiency was noted in skin fibroblasts. The variant was present at >95% heteroplasmy in blood, muscle, and fibroblasts. The variant was absent in his mother although technology performed at the time was limited in detecting low heteroplasmy levels. This variant is absent in the MITOMAP GenBank dataset, gnomAD v3.1.2, and the Helix dataset (PM2_supporting, note the single occurrence in MITOMAP is likely from the reported patient). The computational predictor APOGEE suggests this variant is pathogenic (0.52, range 0-1; PP3). Cybrid studies supported the functional impact of this variant as mutant cybrids had reduced complex I activity and impaired complex I assembly (PS3_supporting; PMID: 16996290). In summary, this variant meets criteria to be classified as uncertain significance for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on October 23, 2023. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PM2_supporting, PP3, PS3_supporting.
Met criteria codes
PM2_Supporting
This variant is absent in in the MITOMAP GenBank dataset, gnomAD v3.1.2, and the Helix dataset (PM2_supporting, note the single occurrence in MITOMAP is likely from the reported patient).
PP3
The computational predictor APOGEE suggests this variant is pathogenic (0.52, range 0-1; PP3).
PS3_Supporting
Cybrid studies supported the functional impact of this variant as mutant cybrids had reduced complex I activity and assembly (PS3_supporting; PMID: 16996290).

Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.